Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

Kevin M. McKown, Laura D. Carbone, Stanley B. Kaplan, Jacob A. Aelion, Kristine M. Lohr, Michael A. Cremer, Juan Bustillo, Miguel Gonzalez, Gurjit Kaeley, Elaine L. Steere, Grant W. Somes, Linda Myers, Jerome M. Seyer, Andrew Kang, Arnold Postlethwaite

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

Original languageEnglish (US)
Pages (from-to)1204-1208
Number of pages5
JournalArthritis and Rheumatism
Volume42
Issue number6
DOIs
StatePublished - Jun 1 1999

Fingerprint

Collagen Type II
Rheumatoid Arthritis
Placebos
Rheumatology
Therapeutics
Arthritis

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. / McKown, Kevin M.; Carbone, Laura D.; Kaplan, Stanley B.; Aelion, Jacob A.; Lohr, Kristine M.; Cremer, Michael A.; Bustillo, Juan; Gonzalez, Miguel; Kaeley, Gurjit; Steere, Elaine L.; Somes, Grant W.; Myers, Linda; Seyer, Jerome M.; Kang, Andrew; Postlethwaite, Arnold.

In: Arthritis and Rheumatism, Vol. 42, No. 6, 01.06.1999, p. 1204-1208.

Research output: Contribution to journalArticle

McKown, KM, Carbone, LD, Kaplan, SB, Aelion, JA, Lohr, KM, Cremer, MA, Bustillo, J, Gonzalez, M, Kaeley, G, Steere, EL, Somes, GW, Myers, L, Seyer, JM, Kang, A & Postlethwaite, A 1999, 'Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis', Arthritis and Rheumatism, vol. 42, no. 6, pp. 1204-1208. https://doi.org/10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U
McKown, Kevin M. ; Carbone, Laura D. ; Kaplan, Stanley B. ; Aelion, Jacob A. ; Lohr, Kristine M. ; Cremer, Michael A. ; Bustillo, Juan ; Gonzalez, Miguel ; Kaeley, Gurjit ; Steere, Elaine L. ; Somes, Grant W. ; Myers, Linda ; Seyer, Jerome M. ; Kang, Andrew ; Postlethwaite, Arnold. / Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. In: Arthritis and Rheumatism. 1999 ; Vol. 42, No. 6. pp. 1204-1208.
@article{ebd71d110a574039b530152789fa280e,
title = "Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis",
abstract = "Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0{\%} of placebo patients; 16.84{\%} of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.",
author = "McKown, {Kevin M.} and Carbone, {Laura D.} and Kaplan, {Stanley B.} and Aelion, {Jacob A.} and Lohr, {Kristine M.} and Cremer, {Michael A.} and Juan Bustillo and Miguel Gonzalez and Gurjit Kaeley and Steere, {Elaine L.} and Somes, {Grant W.} and Linda Myers and Seyer, {Jerome M.} and Andrew Kang and Arnold Postlethwaite",
year = "1999",
month = "6",
day = "1",
doi = "10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U",
language = "English (US)",
volume = "42",
pages = "1204--1208",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

AU - McKown, Kevin M.

AU - Carbone, Laura D.

AU - Kaplan, Stanley B.

AU - Aelion, Jacob A.

AU - Lohr, Kristine M.

AU - Cremer, Michael A.

AU - Bustillo, Juan

AU - Gonzalez, Miguel

AU - Kaeley, Gurjit

AU - Steere, Elaine L.

AU - Somes, Grant W.

AU - Myers, Linda

AU - Seyer, Jerome M.

AU - Kang, Andrew

AU - Postlethwaite, Arnold

PY - 1999/6/1

Y1 - 1999/6/1

N2 - Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

AB - Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=0033000532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033000532&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

DO - 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

M3 - Article

C2 - 10366113

AN - SCOPUS:0033000532

VL - 42

SP - 1204

EP - 1208

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 6

ER -